| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 1,345 | 1,612 | 1,709 | 2,229 | 1,574 | 1,777 | 1,814 | 2,196 | 1,802 | 1,980 | 2,034 | 2,591 | 1,993 | 2,320 | 2,233 | 2,812 | 2,031 | 2,124 | 2,193 | 2,811 | 2,379 |
| Expenses | 1,197 | 1,381 | 1,314 | 1,733 | 1,465 | 1,554 | 1,629 | 1,812 | 1,617 | 1,646 | 1,723 | 2,053 | 1,747 | 1,900 | 1,867 | 2,193 | 1,827 | 1,885 | 1,985 | 2,467 | 2,075 |
| EBITDA | 148 | 231 | 395 | 495 | 109 | 223 | 185 | 384 | 185 | 334 | 312 | 538 | 246 | 420 | 367 | 619 | 204 | 239 | 208 | 344 | 304 |
| Operating Profit % | 9 % | 12 % | 15 % | 19 % | 1 % | 10 % | 5 % | 16 % | 8 % | 14 % | 12 % | 20 % | 10 % | 15 % | 15 % | 20 % | 6 % | 8 % | 7 % | 10 % | 9 % |
| Depreciation | 136 | 138 | 147 | 165 | 162 | 166 | 164 | 184 | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 |
| Interest | 42 | 49 | 50 | 57 | 62 | 83 | 95 | 104 | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 |
| Profit Before Tax | -30 | 44 | 198 | 273 | -115 | -26 | -74 | 95 | -107 | 40 | 19 | 228 | -45 | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -8 |
| Tax | -2 | 7 | 35 | 69 | -6 | 11 | 17 | 45 | -9 | 35 | 9 | 126 | 44 | 98 | 63 | 119 | 3 | 53 | 42 | 52 | 62 |
| Net Profit | -28 | 37 | 163 | 204 | -109 | -37 | -90 | 50 | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 |
| EPS in ₹ | 0.00 | 0.31 | 1.38 | 1.72 | -0.92 | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 | -0.75 | -1.03 | -0.07 | -0.52 |
Piramal Pharma
Piramal Pharma
193.94
-2.07
(-1.06%)
Market Cap
26,095.80 Cr
PE Ratio
-83.14
Volume
16,89,308.00
Day High - Low
196.70 - 192.76
52W High-Low
231.93 - 132.30
Key Fundamentals
Market Cap
26,095.80 Cr
EPS
-2.46
PE Ratio
-83.14
PB Ratio
3.20
Book Value
61.34
EBITDA
1,134.90
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
-3.99
Debt to Equity
0.65
Analyst Rating and Forecast
- By Refinitiv from10 analysts
Actual
Company News
View All News
Piramal Pharma's Bayer sales deal ends December 31, 2026Oct 01, 2026
Piramal Pharma's sales agreement with Bayer Pharmaceuticals will not be renewed and is set to expire on December 31, 2026.
Piramal Pharma gets ₹4.06 Cr GST demand
Sep 29, 2026
Sep 29, 2026Piramal Pharma received a GST demand of ₹4.06 crore plus equivalent penalty for FY21-FY23. The company intends to appeal, citing a meritorious case.
Piramal Pharma's Morpeth facility gets 7 FDA observationsSep 15, 2026
Piramal Pharma's Morpeth facility received seven observations following a US FDA inspection, signalling regulatory scrutiny at the manufacturing site.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,746.40 | #1 4,24,850.20 | 35.03 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 33.00 | |
9,023.00 | 2,46,487.60 | 84.18 | 11,067.00 | 13.95 | 2,568 | 65.50 | 42.63 | |
4,580.00 | 1,76,601.00 | 81.77 | 13,886.20 | 20.34 | 2,138 | 3.28 | 33.68 | |
1,124.70 | 1,12,967.30 | 24.57 | 27,657.90 | 17.64 | 5,026 | -34.90 | 44.59 | |
2,036.90 | 1,11,271.90 | 101.64 | 6,867.80 | 22.01 | 890 | #1 123.93 | 58.45 | |
1,314.60 | 1,07,412.90 | 32.02 | 29,044.60 | 2.24 | 3,870 | -39.18 | 35.91 | |
1,216.00 | 1,03,500.40 | 32.50 | 35,058.60 | 3.90 | 4,158 | -69.10 | 53.92 | |
2,335.00 | 97,974.30 | 47.32 | 14,636.40 | 14.85 | 1,938 | 29.13 | 42.11 | |
1,662.90 | 96,928.20 | 26.10 | 34,145.20 | 5.56 | 3,503 | 25.21 | 47.16 | |
1,953.20 | 89,336.20 | #1 16.15 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 31.37 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-2.19 %
Net Income Growth
-457.74 %
Cash Flow Change
85.21 %
ROE
-456.25 %
ROCE
-82.19 %
EBITDA Margin (Avg.)
-26.51 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 | 17,965 |
| Fixed Assets | 6,106 | 6,879 | 7,469 | 7,990 | 8,133 | 8,684 |
| Capital Work in Progress | 627 | 1,172 | 1,419 | 1,116 | 977 | 1,100 |
| Investments | 123 | 267 | 639 | 385 | 291 | 437 |
| Other Assets | 4,045 | 4,478 | 4,996 | 5,821 | 6,277 | 7,745 |
| Total Equity & Liabilities | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 | 17,965 |
| Current Liabilities | 2,490 | 3,033 | 3,843 | 4,369 | 3,766 | 4,758 |
| Non Current Liabilities | 2,805 | 3,067 | 3,906 | 3,031 | 3,786 | 5,044 |
| Total Equity | 5,605 | 6,697 | 6,774 | 7,911 | 8,126 | 8,163 |
| Reserve & Surplus | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 | 6,836 |
| Share Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 | 1,327 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 | 794 |
| Investing Activities | -4,464 | -1,737 | -1,334 | -416 | -488 | -820 |
| Operating Activities | 598 | 766 | 484 | 1,005 | 892 | 1,653 |
| Financing Activities | 3,977 | 794 | 818 | -422 | -441 | -39 |
Share Holding
| % Holding | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 34.79 % | 0.00 % | 34.79 % | 34.79 % | 34.79 % | 35.02 % | 35.02 % | 35.02 % | 35.02 % | 34.95 % | 34.95 % | 34.95 % | 34.95 % | 34.86 % | 34.86 % | 34.86 % | 34.86 % | 34.80 % |
| FIIs | 20.00 % | 0.00 % | 20.00 % | 20.00 % | 20.00 % | 18.04 % | 32.37 % | 32.51 % | 30.59 % | 31.42 % | 31.73 % | 31.68 % | 31.49 % | 30.86 % | 30.27 % | 29.66 % | 30.18 % | 12.52 % |
| DIIs | 4.86 % | 0.00 % | 5.28 % | 4.99 % | 5.49 % | 7.83 % | 8.02 % | 9.68 % | 12.12 % | 12.95 % | 13.81 % | 14.10 % | 14.78 % | 14.26 % | 14.89 % | 15.69 % | 15.61 % | 14.57 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.42 % | 0.00 % | 11.80 % | 13.94 % | 16.77 % | 16.81 % | 16.95 % | 15.57 % | 15.13 % | 13.94 % | 13.29 % | 13.29 % | 13.11 % | 14.07 % | 14.12 % | 14.11 % | 13.74 % | 14.54 % |
| Others | 32.92 % | 100.00 % | 28.14 % | 26.29 % | 22.95 % | 22.30 % | 7.64 % | 7.22 % | 7.14 % | 6.74 % | 6.22 % | 5.98 % | 5.66 % | 5.95 % | 5.86 % | 5.69 % | 5.61 % | 23.57 % |
| No of Share Holders | 1,79,957 | 1,79,948 | 2,29,960 | 2,41,359 | 2,77,270 | 2,95,773 | 2,97,225 | 2,92,312 | 2,97,996 | 3,06,398 | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 | 4,62,511 | 4,53,830 | 4,50,661 | 4,61,096 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.11 | 0.14 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.05 | 0.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Aug 2023 |  Rights | 5:46 | 02 Aug 2023 | 101.95 | 103.86 |
| 12 Jul 2024 |  Dividend | ₹ 0.11 /share | 12 Jul 2024 | 148.05 | 151.60 |
| 26 Jul 2024 |  Annual General Meeting | NA | 26 Jul 2024 | 157.10 | 166.30 |
| 23 Oct 2024 |  Quarterly Result Announcement | NA | 23 Oct 2024 | 221.30 | 215.15 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 221.25 | 224.00 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 214.95 | 214.90 |
| 16 Jul 2025 | Dividend | ₹ 0.14 /share | 16 Jul 2025 | 214.90 | 216.22 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 216.88 | 202.23 |
| 30 Jul 2025 | Annual General Meeting | NA | 30 Jul 2025 | 199.95 | 205.61 |
| 05 Nov 2025 | Quarterly Result Announcement | NA | 05 Nov 2025 | 203.60 | 200.42 |
| 28 Jan 2026 | Quarterly Result Announcement | NA | 28 Jan 2026 | 168.10 | 152.45 |
| 28 Apr 2026 | Quarterly Result Announcement | NA | 28 Apr 2026 | 147.45 | 168.78 |
| 29 Jul 2026 | Quarterly Result Announcement | NA | 29 Jul 2026 | 179.42 | 193.40 |
| 30 Jul 2026 | Annual General Meeting | NA | 30 Jul 2026 | 168.20 | 195.68 |
Announcements
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private LimitedOct 01, 2026
Oct 01, 2026Clarification On News Item Which Appeared In The
Www.Thehindubusinessline.Com Dated September 30 2026 Captioned Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal PharmaS Aurora Facility.Oct 01, 2026
Oct 01, 2026Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2026
Sep 30, 2026Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2026
Sep 30, 2026Clarification sought from Piramal Pharma LtdSep 30, 2026
Sep 30, 2026Closure of Trading WindowSep 29, 2026
Sep 29, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 29, 2026
Sep 29, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Rating -Niche Ninety
Nine Capability And Certifications (OPC) Private LimitedSep 18, 2026
Sep 18, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA InspectionSep 14, 2026
Sep 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2026
Sep 08, 2026Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingSep 03, 2026
Sep 03, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 26, 2026
Aug 26, 2026Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26Aug 24, 2026
Aug 24, 2026Announcement under Regulation 30 (LODR)-AcquisitionAug 18, 2026
Aug 18, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 18, 2026
Aug 18, 2026Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private LimitedAug 10, 2026
Aug 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 10, 2026
Aug 10, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -Resumption Of Operations At CompanyS Facilities Located At Ahmedabad GujaratAug 03, 2026
Aug 03, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 31, 2026
Jul 31, 2026Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2026
Jul 30, 2026Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 30, 2026
Jul 30, 2026Announcement under Regulation 30 (LODR)-Investor PresentationJul 29, 2026
Jul 29, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2026
Jul 29, 2026Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026Jul 29, 2026
Jul 29, 2026Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July 2026Jul 29, 2026
Jul 29, 2026Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock OptionsJul 29, 2026
Jul 29, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Temporary Suspension Of Operations At CompanyS Facilities Located At Ahmedabad Gujarat.Jul 24, 2026
Jul 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 20, 2026
Jul 20, 2026Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June 2026.
Jul 20, 2026
Jul 20, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 17, 2026
Jul 17, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 09, 2026
Jul 09, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2026
Jul 04, 2026Business Responsibility and Sustainability Reporting (BRSR)Jul 03, 2026
Jul 03, 2026Reg. 34 (1) Annual Report.Jul 03, 2026
Jul 03, 2026Notice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-26Jul 03, 2026
Jul 03, 2026Closure of Trading WindowJun 29, 2026
Jun 29, 2026Clarification On News Item Appearing On NDTV Profit Captioned - "Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?"Jun 23, 2026
Jun 23, 2026Clarification sought from Piramal Pharma LtdJun 23, 2026
Jun 23, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 19, 2026
Jun 19, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2026
Jun 05, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 03, 2026
Jun 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 01, 2026
Jun 01, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2026
May 19, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Digwal Telangana IndiaMay 18, 2026
May 18, 2026Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 10, 2026
May 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 04, 2026
May 04, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeApr 30, 2026
Apr 30, 2026Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Apr 29, 2026
Apr 29, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 40.49
ATR(14)
Less Volatile 6.74
STOCH(9,6)
Neutral 24.53
STOCH RSI(14)
Neutral 25.68
MACD(12,26)
Bearish -1.24
ADX(14)
Weak Trend 21.35
UO
Bearish 43.58
ROC
Downtrend And Accelerating -5.82
WillR
Oversold -80.41
About Piramal Pharma
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Chairperson NameNandini Piramal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
